Free Trial
NASDAQ:GLPG

Galapagos (GLPG) Stock Price, News & Analysis

Galapagos logo
$26.02 +0.01 (+0.04%)
Closing price 03/17/2025 04:00 PM Eastern
Extended Trading
$26.14 +0.12 (+0.46%)
As of 07:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Galapagos Stock (NASDAQ:GLPG)

Key Stats

Today's Range
$25.95
$26.26
50-Day Range
$22.69
$28.79
52-Week Range
$22.36
$34.02
Volume
155,504 shs
Average Volume
182,894 shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.75
Consensus Rating
Strong Sell

Company Overview

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Remove Ads

Galapagos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

GLPG MarketRank™: 

Galapagos scored higher than 4% of companies evaluated by MarketBeat, and ranked 930th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galapagos has received a consensus rating of Strong Sell. The company's average rating score is 1.44, and is based on no buy ratings, 4 hold ratings, and 5 sell ratings.

  • Amount of Analyst Coverage

    Galapagos has only been the subject of 3 research reports in the past 90 days.

  • Read more about Galapagos' stock forecast and price target.
  • Earnings Growth

    Earnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.

  • Price to Book Value per Share Ratio

    Galapagos has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galapagos' valuation and earnings.
  • Percentage of Shares Shorted

    4.54% of the float of Galapagos has been sold short.
  • Short Interest Ratio / Days to Cover

    Galapagos has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Galapagos has recently increased by 25.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Galapagos does not currently pay a dividend.

  • Dividend Growth

    Galapagos does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.54% of the float of Galapagos has been sold short.
  • Short Interest Ratio / Days to Cover

    Galapagos has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Galapagos has recently increased by 25.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Galapagos has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Galapagos this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Galapagos to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galapagos insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.91% of the stock of Galapagos is held by insiders.

  • Percentage Held by Institutions

    Only 32.46% of the stock of Galapagos is held by institutions.

  • Read more about Galapagos' insider trading history.
Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

GLPG Stock News Headlines

Morgan Stanley Sticks to Their Sell Rating for Galapagos (GLPG)
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Galapagos to Present at Upcoming Investor Conferences
Disount To Net Cash For A Promising CAR-T Company
Galapagos price target lowered to EUR 22 from EUR 28 at Deutsche Bank
See More Headlines

GLPG Stock Analysis - Frequently Asked Questions

Galapagos' stock was trading at $27.50 at the start of the year. Since then, GLPG shares have decreased by 5.4% and is now trading at $26.02.
View the best growth stocks for 2025 here
.

Galapagos NV (NASDAQ:GLPG) posted its quarterly earnings data on Thursday, February, 21st. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.82.

Galapagos (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos' top institutional shareholders include Gilead Sciences Inc. (25.35%), Tang Capital Management LLC (3.28%), Deep Track Capital LP (1.18%) and Segall Bryant & Hamill LLC (1.04%).

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
2/21/2019
Today
3/17/2025
Next Earnings (Estimated)
4/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLPG
Employees
1,123
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$26.75
High Stock Price Target
$31.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+2.8%
Consensus Rating
Strong Sell
Rating Score (0-4)
1.44
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$275.65 million
Price / Cash Flow
N/A
Book Value
$47.57 per share
Price / Book
0.55

Miscellaneous

Free Float
63,979,000
Market Cap
$1.71 billion
Optionable
Optionable
Beta
0.18

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:GLPG) was last updated on 3/18/2025 by MarketBeat.com Staff
From Our Partners